Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Completed · Phase 1/Phase 2
Conditions studied: Carcinoma, Non-small-cell Lung
In brief
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Key facts
- Study ID
- NCT00047801
- Run by
- Telik
- People needed
- 28
- Starts
- 2002-10-01
- Expected to finish
- 2004-09-01
- Last updated by the study team
- 2011-07-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute Medical Group — Los Angeles, California, United States
- UCLA Medical Center — Los Angeles, California, United States
- Indiana University Cancer Center — Indianapolis, Indiana, United States
- M.D. Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.